The Difference Between Rasagiline and Selegiline

Rasagiline and selegiline are the only MAO-BIs approved by the U.S. Food and Drug Administration (FDA). Both are relatively selective and irreversible, but have some significant differences mainly in their metabolites: amphetamine derivatives and aminoindans. The symptomatic effects of both MAO-BIs have been well documented in prospective RCTs of both drugs in early Parkinson's disease.

Selegiline is the first selectiveMAO-B inhibitor that is partially metabolized in the body to l-methamphetamine (l-methamphetamine), one of the two enantiomers of methamphetamine. While these metabolites may contribute to selegiline's ability to inhibit the reuptake of the neurotransmitters dopamine and norepinephrine, they have also been associated with orthostatic hypotension and hallucinations in some individuals. Rasagiline is metabolized to 1(R)-aminoindan, which does not have amphetamine-like characteristics and has neuroprotective properties in cellular and animal models.

The original drug of rasagiline has been launched in China and has entered the category of Class B medical insurance. The common name is rasagiline mesylate tablets, and the specifications areThe price of each box of 1mg*14 tablets may be around RMB 600. The price of the Turkish version of rasagiline's original drug, 1mg*30 tablets, per box sold overseas may be around RMB 310 (the price may fluctuate due to exchange rates). There are also generic drugs produced in other countries. The price of 1mg*100 tablets per box produced by Indian pharmaceutical factories may be around RMB 240 (the price may fluctuate due to the exchange rate). The pharmaceutical ingredients of generic drugs are basically the same as those of domestic and foreign original drugs. For specific prices and drug information, please consult Yaode Medical Consultant.